PBC Progression and Benefits of Early Diagnosis

May 2025

Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease that often begins with the presence of anti-mitochondrial antibodies (AMA)—even before liver tests become abnormal. In this video, we explore the significance of AMA positivity, why early detection matters, and how untreated cholestasis can silently progress to fibrosis, bile duct loss, and ultimately liver failure.

Learn how to interpret AMA results in asymptomatic patients, the importance of monitoring alkaline phosphatase and serum bile acids, and why abnormal bilirubin is a late marker of disease. We also discuss common missteps in diagnosis, the impact of gender on outcomes, and why men with PBC often fare worse—likely due to later diagnosis or differing disease biology.

Clinicians are encouraged to maintain a high index of suspicion for PBC in patients with a cholestatic liver enzyme pattern—even if symptoms are subtle like pruritus. Most importantly, this video emphasizes a critical message: early treatment changes outcomes. With timely intervention, liver transplant for PBC has become far less common.